How it works
A triple GIP, GLP-1, and glucagon receptor agonist combining incretin signaling, satiety, and energy expenditure.
Who it is for
RETA is studied for obesity, overweight, type 2 diabetes, and metabolic fatty-liver disease.
Key benefits
Key benefits include metabolism, glucose regulation, food intake, and body-composition endpoints